Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia

a retrospective study on behalf of the chronic malignancies working party of the EBMT

Gwendolyn van Gorkom, Michel van Gelder, Dirk Jan Eikema, Henric Jan Blok, M. T. van Lint, Yener Koc, Fabio Ciceri, Dietrich Beelen, Patrice Chevallier, Dominik Selleslag, Didier Blaise, Roberto Foá, Paolo Corradini, Luca Castagna, Carol Moreno, Carlos Solano, Lutz Peter Müller, Johanna Tischer, Inken Hilgendorf, Michael Hallek & 6 others Jörg Bittenbring, Matthias Theobald, Johannes Schetelig, Nicolaus Kröger, on behalf of the CLL subcommittee, Chronic Malignancies Working Party of the EBMT

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalBone Marrow Transplantation
DOIs
Publication statusAccepted/In press - Dec 18 2017

Fingerprint

Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
B-Cell Chronic Lymphocytic Leukemia
Retrospective Studies
Cyclophosphamide
Transplantation
Neoplasms
Tissue Donors
Incidence
Recurrence
Registries
Cohort Studies
Transplants

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia : a retrospective study on behalf of the chronic malignancies working party of the EBMT. / van Gorkom, Gwendolyn; van Gelder, Michel; Eikema, Dirk Jan; Blok, Henric Jan; van Lint, M. T.; Koc, Yener; Ciceri, Fabio; Beelen, Dietrich; Chevallier, Patrice; Selleslag, Dominik; Blaise, Didier; Foá, Roberto; Corradini, Paolo; Castagna, Luca; Moreno, Carol; Solano, Carlos; Müller, Lutz Peter; Tischer, Johanna; Hilgendorf, Inken; Hallek, Michael; Bittenbring, Jörg; Theobald, Matthias; Schetelig, Johannes; Kröger, Nicolaus; on behalf of the CLL subcommittee; Chronic Malignancies Working Party of the EBMT.

In: Bone Marrow Transplantation, 18.12.2017, p. 1-9.

Research output: Contribution to journalArticle

van Gorkom, G, van Gelder, M, Eikema, DJ, Blok, HJ, van Lint, MT, Koc, Y, Ciceri, F, Beelen, D, Chevallier, P, Selleslag, D, Blaise, D, Foá, R, Corradini, P, Castagna, L, Moreno, C, Solano, C, Müller, LP, Tischer, J, Hilgendorf, I, Hallek, M, Bittenbring, J, Theobald, M, Schetelig, J, Kröger, N, on behalf of the CLL subcommittee & Chronic Malignancies Working Party of the EBMT 2017, 'Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT', Bone Marrow Transplantation, pp. 1-9. https://doi.org/10.1038/s41409-017-0023-2
van Gorkom, Gwendolyn ; van Gelder, Michel ; Eikema, Dirk Jan ; Blok, Henric Jan ; van Lint, M. T. ; Koc, Yener ; Ciceri, Fabio ; Beelen, Dietrich ; Chevallier, Patrice ; Selleslag, Dominik ; Blaise, Didier ; Foá, Roberto ; Corradini, Paolo ; Castagna, Luca ; Moreno, Carol ; Solano, Carlos ; Müller, Lutz Peter ; Tischer, Johanna ; Hilgendorf, Inken ; Hallek, Michael ; Bittenbring, Jörg ; Theobald, Matthias ; Schetelig, Johannes ; Kröger, Nicolaus ; on behalf of the CLL subcommittee ; Chronic Malignancies Working Party of the EBMT. / Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia : a retrospective study on behalf of the chronic malignancies working party of the EBMT. In: Bone Marrow Transplantation. 2017 ; pp. 1-9.
@article{1db0a134f4fc4487b858beca11c2a734,
title = "Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT",
abstract = "Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74{\%} males) were included; 38{\%} received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38{\%}, respectively. PFS at 2 and 5 yrs was 38 and 31{\%}, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44{\%}, respectively. CI of relapse at 2 and 5 yrs were 22 and 26{\%}, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.",
author = "{van Gorkom}, Gwendolyn and {van Gelder}, Michel and Eikema, {Dirk Jan} and Blok, {Henric Jan} and {van Lint}, {M. T.} and Yener Koc and Fabio Ciceri and Dietrich Beelen and Patrice Chevallier and Dominik Selleslag and Didier Blaise and Roberto Fo{\'a} and Paolo Corradini and Luca Castagna and Carol Moreno and Carlos Solano and M{\"u}ller, {Lutz Peter} and Johanna Tischer and Inken Hilgendorf and Michael Hallek and J{\"o}rg Bittenbring and Matthias Theobald and Johannes Schetelig and Nicolaus Kr{\"o}ger and {on behalf of the CLL subcommittee} and {Chronic Malignancies Working Party of the EBMT}",
year = "2017",
month = "12",
day = "18",
doi = "10.1038/s41409-017-0023-2",
language = "English",
pages = "1--9",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia

T2 - a retrospective study on behalf of the chronic malignancies working party of the EBMT

AU - van Gorkom, Gwendolyn

AU - van Gelder, Michel

AU - Eikema, Dirk Jan

AU - Blok, Henric Jan

AU - van Lint, M. T.

AU - Koc, Yener

AU - Ciceri, Fabio

AU - Beelen, Dietrich

AU - Chevallier, Patrice

AU - Selleslag, Dominik

AU - Blaise, Didier

AU - Foá, Roberto

AU - Corradini, Paolo

AU - Castagna, Luca

AU - Moreno, Carol

AU - Solano, Carlos

AU - Müller, Lutz Peter

AU - Tischer, Johanna

AU - Hilgendorf, Inken

AU - Hallek, Michael

AU - Bittenbring, Jörg

AU - Theobald, Matthias

AU - Schetelig, Johannes

AU - Kröger, Nicolaus

AU - on behalf of the CLL subcommittee

AU - Chronic Malignancies Working Party of the EBMT

PY - 2017/12/18

Y1 - 2017/12/18

N2 - Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.

AB - Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.

UR - http://www.scopus.com/inward/record.url?scp=85038393674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038393674&partnerID=8YFLogxK

U2 - 10.1038/s41409-017-0023-2

DO - 10.1038/s41409-017-0023-2

M3 - Article

SP - 1

EP - 9

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -